Schiehallion Fund Limited (The) Directorate Change (5965K)
02 Settembre 2021 - 5:30PM
UK Regulatory
TIDMMNTN TIDMMNTC
RNS Number : 5965K
Schiehallion Fund Limited (The)
02 September 2021
The Schiehallion Fund Limited
(the "Company")
Legal Entity Identifier: 213800NQOLJA1JCWXQ56
The Board is delighted to announce the appointments of David
Chiswell and Richard Holmes as non-executive Directors of the
Company with effect from 2 September 2021.
David Chiswell, Ph.D. has over 30 years' experience in the
biotechnology industry. In 1990, Dr. Chiswell co-founded Cambridge
Antibody Technology and served as its chief executive officer
("CEO") from 1996 to 2002. He served as CEO of Kymab Ltd from 2015
to 2018 and prior to that as CEO of Nabriva Therapeutics from 2009
to 2012. He served as a director of Arakis and non-executive
chairman of Sosei, Arrow Therapeutics, Daniolabs, Nabriva
Therapeutics and Kymab. Dr Chiswell is currently chairman of
Albireo Pharma Inc and, Epsilogen Ltd and a board member of
Avillion Bond 2 Development 2 GP.
Dr. Chiswell is also a past chairman of the UK BioIndustry
Association and his contributions to the field were recognized in
2006 when he was awarded the OBE by HM the Queen for services to
the biotechnology industry.
Richard completed a BSc in Economics at London School of
Economics and then a Masters at Warwick University. He worked in
various marketing roles at Unilever in London, Paris and Milan from
1983 to 1995. He then moved to Boots Plc where he was marketing
director and launched the Boots Advantage Card and set up
Boots.com. In 2007, he moved to Guernsey to join the board of
Specsavers Optical Group as group marketing director. He retired
from full time work in 2018. He currently holds various
non-executive positions, including Lok 'n Store Plc, Moorfields Eye
Hospital and Citizens Advice Guernsey.
There is no further information required to be disclosed under
Listing Rule 9.6.13.
Alter Domus (Guernsey) Limited
Company Secretary
2 September 2021
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAELLFBFKLLBBK
(END) Dow Jones Newswires
September 02, 2021 11:30 ET (15:30 GMT)
Grafico Azioni The Schiehallion (LSE:MNTN)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni The Schiehallion (LSE:MNTN)
Storico
Da Giu 2023 a Giu 2024